Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines

  • Olivan, Mireia|||0000-0002-8464-0827
  • Rigau, M.
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Garcia, M..
  • Montes, Melania|||0000-0002-4268-6608
  • Sequeiros, T.
  • Regis, Lucas|||0000-0001-7121-1946
  • Celma, Ana|||0000-0002-3128-3811
  • Planas, J.
  • Placer, José
  • Reventós, J.
  • de Torres, Inés|||0000-0002-5495-9140
  • Doll, Andreas|||0000-0001-8965-8682
  • Morote Robles, Juan|||0000-0002-2168-323X
Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. The aim of this study was to analyze how chronic treatment with statins, aspirin, and their combination influenced the risk of PCa detection. The tumorigenic properties of these treatments were evaluated by proliferation, colony formation, invasion, and migration assays using different PCa cell lines, in order to assess how these treatments act at molecular level. The results showed that a combination of statins and aspirin enhances the effect of individual treatments and seems to reduce the risk of PCa detection (OR: 0.616 (95% CI: 0.467-0.812), P < 0.001). However, if treatments are maintained, aspirin (OR: 1.835 (95% CI: 1.068-3.155), P = 0.028) or the combination of both drugs (OR: 3.059 (95% CI: 1.894-4.939), P < 0.001) represents an increased risk of HGPCa. As observed at clinical level, these beneficial effects in vitro are enhanced when both treatments are administered simultaneously, suggesting that chronic, concomitant treatment with statins and aspirin has a protective effect on PCa incidence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer

  • Sequeiros, Tamara|||0000-0002-0908-2263
  • Rigau, Marina|||0000-0002-1691-454X
  • Chiva, Cristina
  • Montes, Melania|||0000-0002-4268-6608
  • Garcia-Grau, Iolanda
  • García, Marta|||0000-0001-5155-4730
  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Celma, Ana|||0000-0002-3128-3811
  • Bijnsdorp, Irene
  • Campos, Alexandre
  • Di Mauro, Primiano
  • Borrós, Salvador|||0000-0002-4003-0381
  • Reventós, Jaume
  • Doll, Andreas|||0000-0001-8965-8682
  • Paciucci, Rosanna|||0000-0001-5651-5933
  • Pegtel, Michiel
  • de Torres, Inés|||0000-0002-5495-9140
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Olivan, Mireia|||0000-0002-8464-0827
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches-such as selected reaction monitoring (SRM)-as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of prostate tumor overexpressed 1 in cancer progression

  • Cánovas, Verónica|||0000-0002-1994-5763
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paciucci, Rosanna|||0000-0001-5651-5933
Prostate-Tumor-Overexpressed-1 (PTOV1) is a conserved adaptor protein discovered as overexpressed in prostate cancer. Since its discovery, the number of binding partners and associated cellular functions has increased and helped to identify PTOV1 as regulator of gene expression at transcription and translation levels. Its overexpression is associated with increased tumor grade and proliferation in prostate cancer and other neoplasms, including breast, ovarian, nasopharyngeal, squamous laryngeal, hepatocellular and urothelial carcinomas. An important contribution to higher levels of PTOV1 in prostate tumors is given by the frequent rate of gene amplifications, also found in other tumor types. The recent resolution of the structure by NMR of the PTOV domain in PTOV2, also identified as Arc92/ACID1/MED25, has helped to shed light on the functions of PTOV1 as a transcription factor. In parallel, by studying its interaction with RACK1, we have discovered PTOV1 action in promoting mRNAs translation. Here, we will focus on the role of PTOV1 in cancer, re-examine its pro-oncogenic effects and re-evaluate the most relevant interactions and evidences of its cellular functions. The data are used to formulate a model for the mechanisms of action of PTOV1 in line with its recently described activities and cellular pathways modulated in cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells

  • Cánovas, Verónica|||0000-0002-1994-5763
  • Puñal, Yolanda
  • Maggio, Valentina|||0000-0002-4985-5611
  • Redondo, Enric
  • Marín Aguilera, Mercedes
  • Mellado, Begoña|||0000-0002-8088-5966
  • Olivan, Mireia|||0000-0002-8464-0827
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paciucci, Rosanna|||0000-0001-5651-5933
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. Here, we investigated the role of PTOV1 in prostate cancer survival to docetaxel and self-renewal ability. Transduction of PTOV1 in docetaxel-sensitive Du145 and PC3 cells significantly increased cell survival after docetaxel exposure and induced docetaxel-resistance genes expression (ABCB1, CCNG2 and TUBB2B). In addition, PTOV1 induced prostatospheres formation and self-renewal genes expression (ALDH1A1, LIN28A, MYC and NANOG). In contrast, Du145 and PC3 cells knockdown for PTOV1 significantly accumulated in the G2/M phase, presented a concomitant increased subG1 peak, and cell death by apoptosis. These effects were enhanced in docetaxel-resistant cells. Analyses of tumor datasets show that PTOV1 expression significantly correlated with prostate tumor grade, drug resistance (CCNG2) and self-renewal (ALDH1A1, MYC) markers. These genes are concurrently overexpressed in most metastatic lesions. Metastases also show PTOV1 genomic amplification in significant co-occurrence with docetaxel-resistance and self-renewal genes. Our findings identify PTOV1 as a promoter of docetaxel-resistance and self-renewal characteristics for castration resistant prostate cancer. The concomitant increased expression of PTOV1, ALDH1A1 and CCNG2 in primary tumors, may predict metastasis and bad prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis

  • Altadill, Tatiana
  • Dowdy, Tyrone M.
  • Gill, Kirandeep
  • Reques, Armando|||0000-0002-7197-9354
  • Menon, Smrithi S.
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • López-Gil, Carlos|||0000-0001-6540-1225
  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Garcia, Angel
  • Reventos, Jaume
  • Byers, Stephen W.
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Cheema, Amrita K.
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer (EC) remains the most common malignancy of the genital tract among women in developed countries. Although much research has been performed at genomic, transcriptomic and proteomic level, there is still a significant gap in the metabolomic studies of EC. In order to gain insights into altered metabolic pathways in the onset and progression of EC carcinogenesis, we used high resolution mass spectrometry to characterize the metabolomic and lipidomic profile of 39 human EC and 17 healthy endometrial tissue samples. Several pathways including lipids, Kynurenine pathway, endocannabinoids signaling pathway and the RNA editing pathway were found to be dysregulated in EC. The dysregulation of the RNA editing pathway was further investigated in an independent set of 183 human EC tissues and matched controls, using orthogonal approaches. We found that ADAR2 is overexpressed in EC and that the increase in expression positively correlates with the aggressiveness of the tumor. Furthermore, silencing of ADAR2 in three EC cell lines resulted in a decreased proliferation rate, increased apoptosis, and reduced migration capabilities in vitro. Taken together, our results suggest that ADAR2 functions as an oncogene in endometrial carcinogenesis and could be a potential target for improving EC treatment strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan, Mireia|||0000-0002-8464-0827
  • García, Marta
  • Suárez, Leticia|||0000-0002-3864-4616
  • Guiu, Marc|||0000-0002-7083-986X
  • Gros, Laura
  • Méndez Fernández, Olga
  • Rigau, Marina|||0000-0002-1691-454X
  • Reventós, Jaume
  • Segura, Miguel F.|||0000-0003-0916-3618
  • de Torres, Inés|||0000-0002-5495-9140
  • Planas, Jacques|||0000-0002-0222-584X
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Gomis, Roger R..|||0000-0001-6473-2858
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. Our main objective was to unveil novel molecules associated with choosing the bone as a metastatic niche. For this purpose, we generated and characterized a cell line with increased tropism to bone. Its molecular analysis has led us to identify factors with a potential role in bone metastasis that could also be used as biomarkers of disease progression. These data help us to understand the mechanisms that increase bone metastasis penetrance of PCa cells and could provide new therapeutic tools in the future for patients with worse prognoses. About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.